Teva Pharmaceutical Industries Ltd
TEVA:NYSE
| Last | Change / % Change | Dividend Yield | Volume | Avg Volume (10 day) |
|---|---|---|---|---|
| 50.67 | -0.78 -1.52% | 2.58% | 3,444,795 | 5.9M |
Latest News Headlines for Teva Pharmaceutical Industries Ltd
Editor Note: For more information about this release, please scroll to bottom. NEW YORK, April 23, 2014 /PRNewswire/ -- Today, Analysts Review released its analysts' notes regarding Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN), Humana Inc. (NYSE: HUM), Eli Lilly & Co. (NYSE: LLY), Teva Pharmaceutical Industries Limited (NYSE: TEVA) and Cigna Corp (NYSE: CI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1465-100free.
Third Phase 3 Trial of Custirsen to Receive FDA Fast Track Designation BOTHELL, Wash. and VANCOUVER, British Columbia, April 23, 2014 /CNW/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the investigation of custirsen when administered in combination with cabazitaxel/prednisone for the treatment of men with metastatic castrate-resistant prostate cancer (CRPC) following prior treatment with a docetaxel-containing regimen.
Third Phase 3 Trial of Custirsen to Receive FDA Fast Track Designation BOTHELL, Wash. and VANCOUVER, British Columbia, April 23, 2014 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the investigation of custirsen when administered in combination with cabazitaxel/prednisone for the treatment of men with metastatic castrate-resistant prostate cancer (CRPC) following prior treatment with a docetaxel-containing regimen.
Company Background
Teva Pharmaceutical Industries Ltd (Teva) is an Israel-based pharmaceutical and drug company. It develops, produces and markets generic drugs in all treatment categories. The Company has a pharmaceutical business, whose principal products include Copaxone and Azilect. Teva's active pharmaceutical ingredient (API) business provides vertical integration to Teva's own pharmaceutical production. The Company's global operations are conducted from North and Latin America to Europe and Asia. Teva operates a number of subsidiaries in such countries as Canada, Croatia, the Czech Republic, France, Germany, Hungary, Ireland, Israel, Japan, Poland, the Russian Federation, Spain, the Netherlands, the United Kingdom and the United States. In February 2014, the Company's subsidiary, Train Merger Sub, Inc, fully acquired NuPathe Inc.
| Bid/Size | Ask/Size |
|---|---|
| -- / -- | -- / -- |
| Price Open | Previous Close |
|---|---|
| 51.22 | 50.67 |
| Day High | Day Low |
|---|---|
| 51.73 | 50.67 |
| 52wk High/Date | 52wk Low/Date |
|---|---|
| 54.70 / 4/2/2014 | 36.26 / 11/5/2013 |
| % off 52wk High | % off 52wk Low |
|---|---|
| -7.37% | 39.74% |
| Beta (5 Yr) | Market Capitalization |
|---|---|
| 0.7 | 48.1B Large Cap |
| Shares Outstanding | Volatility Avg |
|---|---|
| 949.7M | 23.26 |
| EPS(TTM) | P/E Ratio |
|---|---|
| 1.49 | 33.9 |
| Dividend Announcement | Dividend Yield |
|---|---|
| 2/8/2014 | 2.58% |
| Ex-Date | Date of Record |
|---|---|
| 2/20/2014 | 2/24/2014 |
| Payable | Payable Date |
|---|---|
| 0.3447 - QRTR | 3/10/2014 |
Peers Information HelpTEVA Teva Pharmaceutical Industries Ltd vs. Peers
| Peers | |
|---|---|
TEVA Teva Pharmaceutical Industries Ltd | 26.42% |
Biogen Idec Inc | 9.52% |
TEVA Teva Pharmaceutical Industries Ltd | 2.58% |
Biogen Idec Inc | -- |
TEVA Teva Pharmaceutical Industries Ltd | -1.52% |
Biogen Idec Inc | 0.18% |